Health Care·Biotechnology·$2.1B
Sarepta Therapeutics (SRPT) is a biotechnology company focused on developing innovative gene therapies for rare diseases, particularly muscular dystrophies. With a market cap of $2 billion, it plays a crucial role in advancing treatment options in the health care sector, especially for conditions that currently have limited therapies available.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its therapies.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
+1863.38%
Avg Stock Reaction
-2.91%
In the last quarter, Sarepta reported an EPS of -$3.58, significantly missing expectations. The stock reacted positively the following day, gaining 0.69%.
Management Promises & Guidance
Analysts are cautiously optimistic about Sarepta's upcoming earnings, expecting a rebound in EPS and revenue. The consensus estimates reflect a potential recovery after recent misses.
Bull Case
If Sarepta meets or exceeds the EPS and revenue estimates, it could signal a turnaround in financial performance, boosting investor confidence.
Bear Case
Conversely, if the company fails to meet expectations again, it may raise concerns about its growth prospects and lead to a further decline in stock price.
EPS
$1.05Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.
Revenue
$475MRevenue figures will provide insight into the company's sales performance and market demand for its therapies.
The print will turn on these two things.
Q1
Will the EPS meet or exceed the consensus estimate of $1.05?
A positive EPS could indicate a recovery in profitability, which is critical for restoring investor confidence.
Q2
What revenue figures will the company report compared to the consensus of $475M?
Revenue performance is essential to gauge market demand for Sarepta's therapies and its overall financial health.
Why consensus could be wrong
The Street may be underestimating the potential for Sarepta to rebound, given its recent advancements in clinical trials and operational improvements.
Supporting Evidence
The company has shown a strong ability to surprise positively on EPS in the past, with a 75% beat rate.
Despite recent misses, the stock has reacted positively in some instances, indicating underlying strength.
Options pricing suggests a significant move, indicating that investors are anticipating a major shift.
Key Risk
If the company reports strong clinical trial results alongside solid financials, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it follows a series of disappointing results, and investors are looking for signs of recovery.
Bull Confirmed If
Achieving an EPS of $1.05 or higher would confirm the bull case and suggest a strong recovery.
Bear Confirmed If
An EPS below the consensus estimate of $1.05 would reinforce the bear case and raise concerns about the company's future.
Implied Move
±22.97%
Historical Avg
±5.0%
The options market is pricing in a significant potential movement in the stock, indicating heightened uncertainty ahead of the earnings report.
Options are pricing ±23.0% while SRPT has averaged ±5.0% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Sarepta beats expectations, history suggests a potential stock increase of around 0.43%, confirming a positive turnaround narrative.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
Should the company miss expectations, history indicates a likely decline of about 12.94%, which could further shake investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026